mRNA-3705
Phase 2Recruiting 0 views this week 0 watching
0
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Methylmalonic Acidemia
Conditions
Methylmalonic Acidemia
Trial Timeline
Mar 8, 2022 → Apr 2, 2034
NCT ID
NCT05295433About mRNA-3705
mRNA-3705 is a phase 2 stage product being developed by Moderna for Methylmalonic Acidemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05295433. Target conditions include Methylmalonic Acidemia.
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05295433 | Phase 2 | Recruiting |
| NCT04899310 | Phase 2 | Active |
Competing Products
4 competing products in Methylmalonic Acidemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| "The MaP Study": Mapping the Patient Journey in MMA and PA | Moderna | Preclinical | 0 |
| mRNA-3704 | Moderna | Phase 2 | 0 |
| mRNA-3705 | Moderna | Phase 2 | 0 |
| Carglumic Acid | Recordati | Pre-clinical | 30 |